Drugs / TPC
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05806060 Comparator | Apr 2023 → May 2026 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TPC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05806060 ↗ |
| Known as | Nab-P | “nab-palitaxel (Nab-P)” NCT05806060 ↗ |